eACT (epilepsy: Adherence in children and technology) Save

Date Added
May 4th, 2019
PRO Number
Pro00087259
Researcher
Janelle Wagner

List of Studies

Silhouette
Keywords
Children's Health, Epilepsy, Pediatrics
Summary

The aim of this multi-site study is to evaluate the effectiveness of mHealth intervention strategies for improving anti-epileptic drug adherence in caregivers of young children with epilepsy. A 2-month baseline period will be followed by two stages. In Stage 1 (3-months), caregivers will received either 1) a mHealth education module and automated digital reminders or 2) the mHealth education module, automated digital reminders, and individualized adherence feedback based. In Stage 2 (2-months), caregivers will either receive 1) continued individualized adherence feedback or 2) individualized adherence feedback and a mHealth problem-solving module. The primary outcome is electronically-monitored adherence. Secondary outcomes include seizure severity/frequency, quality of life and healthcare utilization.

Institution
MUSC
Recruitment Contact
Millie Griffin
843-792-4653
grifm@musc.edu

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy Save

Date Added
March 26th, 2019
PRO Number
Pro00085211
Researcher
Ekrem Kutluay

List of Studies


Profiles_link
Keywords
Epilepsy
Summary

This study is to evaluate how safe the study drug XEN1101 is for patients with focal epilepsy when it is taken with the patients standard epileptic medications.

This investigational drug has been tested in healthy volunteers but this is the first time it will be tested in participants with focal-onset epilepsy. The study will last about 24 weeks and participants will need to visit the research clinic at least 10 times during the study. Visits will be approximately every 2 weeks, after the first two weekly visits folllowing the start of study treatment.

Institution
MUSC
Recruitment Contact
Robin Bulgarino
843-792-1115
Bulgarino@musc.edu

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerablity of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients with Developmental and/or Epileptic Encephalopathies (ELEKTRA). Save

Date Added
January 22nd, 2019
PRO Number
Pro00083332
Researcher
Jonathan Halford

List of Studies


Profiles_link
Keywords
Epilepsy
Summary

The primary objective of this study is to investigate the effect on the frequency of all seizures in pediatric patients with developmental and/or epileptic encephalopathies treated with TAK-935 as adjunctive therapy compared to placebo, as well as evaluate the safety and tolerability of the study drug.

Study TAK-935-2002 includes pediatric patients (aged 2- 17 years) with Dravet syndrome experiencing convulsive seizures and and Lennox Gastaut syndrome experiencing drop seizures. The study consists of 2 main periods: a 4-6 week screening/baseline period followed by a 20 week treatment period. The treatment period consists of a 8 week dose optimization period followed by a 12 week maintenance period. There will be approximately 7 clinic visits and 4 phone visits over 10 months.

Institution
MUSC
Recruitment Contact
Rebecca Hamrick
843-792-3855
hamrickr@musc.edu

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy Save

Date Added
February 13th, 2018
PRO Number
Pro00072354
Researcher
Jonathan Halford

List of Studies


Profiles_link
Keywords
Epilepsy
Summary

This in an exploratory study and the information obtained may lead to new findings regarding the treatment of seizures in adults with drug-resistant focal epilepsy. This study will explore the effectiveness, safety, and of a medication called natalizumab.

Institution
MUSC
Recruitment Contact
Rebecca Hamrick
843-792-3855
hamrickr@musc.edu

NSF 1649865 EAGER: Next-Generation Neural Data Analysis (NGNDA) Platform: Massive Parallel Analysis of Multi-Modal Brain Networks Save

Date Added
April 18th, 2017
PRO Number
Pro00064530
Researcher
Jonathan Halford

List of Studies


Profiles_link
Keywords
Epilepsy
Summary

This project proposes to develop a system to analyze electroencephalography (EEG) and magnetic resonance imaging (MRI) data from clinical studies of patients with epileptic seizures. This will be called the Next-Generative Neural Data Analysis (NGNDA) platform. This system will use new high-performance computing tools and algorithms to analyze high-dimensional brain data from EEG and MRI. The plan is to create tools for analyzing these big data clinical studies that clinicians can use to improve the care of patients with epilepsy.

Institution
MUSC
Recruitment Contact
Rebecca Hamrick
843-792-3855
hamrickr@musc.edu

A Pivotal, Phase III Trial of Detecting Generalized Tonic-Clonic Seizures with a Seizure Detection and Warning System in Epilepsy Patients Save

Date Added
March 24th, 2015
IRB Number
20848
Researcher
Jonathan Halford

List of Studies


Profiles_link
Keywords
Epilepsy
Summary

The goal of this study is to determine the effectiveness of the Companion™ device to detect GTC seizures and alert someone to the seizure.

Institution
MUSC
Recruitment Contact
Becky Hamrick
(843) 792-3855
hamrickr@musc.edu

Change_preferences

-- OR --

Create_login